Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Enanta Pharmaceuticals Inc (Enanta) is a clinical-stage biotechnology company that develops small molecule drugs for viral and immune infections. The company’s pipeline products include EDP-514, a core inhibitor that treats hepatitis B virus (HBV); zelicapavir (EDP-938), a N-protein inhibitor for the respiratory syncytial virus (RSV); EDP-323 and EDP-235, are L-protein inhibitor and 3CL protease inhibitors that target respiratory syncytial virus and COVID-19. It works in partnership with the National Institute of Allergy and Infectious Diseases, AbbVie Inc, Novartis, and Shionogi Inc to discover protease inhibitor compounds. Enanta is headquartered in Watertown, Massachusetts, the US
Headquarters
United States of America
Address
4 Kingsbury Avenue, Watertown, Massachusetts, 02472
Website
www.enanta.com
Telephone
1 302 6365400
No of Employees
120
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ENTA (NASD)
Revenue (2024)
$65.3M
-3.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
29.4%
(2024 vs 2023)
Market Cap*
$366.4M
Net Profit Margin (2024)
XYZ
26.9%
(2024 vs 2023)
* As of and is in US$
Enanta Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Liver Drugs: |
| EDP-514: Hepatitis B Virus |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Enanta Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Watertown | Rahway | New York City | Cambridge | Foster City |
| State/Province | Massachusetts | New Jersey | New York | Cambridgeshire | California |
| No. of Employees | 120 | 75,000 | 75,000 | 96,100 | 17,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bruce L. A. Carter, Ph.D. | Chairman | Executive Board | 2015 | 81 |
| Jay R. Luly, Ph.D | Chief Executive Officer; President; Director | Executive Board | 2003 | 68 |
| Paul J. Mellett | Chief Administrative Officer; Chief Financial Officer | Senior Management | 2024 | 69 |
| Matthew P. Kowalsky | Secretary; Chief Legal Officer | Senior Management | 2024 | 52 |
| Scott T. Rottinghaus, M.D. | Chief Medical Officer | Senior Management | 2022 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer